Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis.

Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH.

Heart Fail Rev. 2015 Mar;20(2):193-201. doi: 10.1007/s10741-014-9453-8. Review.

PMID:
25034701
2.

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis.

Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J.

PLoS One. 2014 Mar 5;9(3):e90555. doi: 10.1371/journal.pone.0090555.

3.

Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.

Lund LH, Benson L, Dahlström U, Edner M, Friberg L.

JAMA. 2014 Nov 19;312(19):2008-18. doi: 10.1001/jama.2014.15241.

PMID:
25399276
4.

Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction.

Agarwal V, Briasoulis A, Messerli FH.

Heart Fail Rev. 2013 Jul;18(4):429-37. doi: 10.1007/s10741-012-9329-8. Review.

PMID:
22678768
5.

Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.

Verbrugge FH, Duchenne J, Bertrand PB, Dupont M, Tang WH, Mullens W.

Am J Cardiol. 2013 Dec 15;112(12):1913-20. doi: 10.1016/j.amjcard.2013.08.013.

PMID:
24286620
6.
7.

How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).

Wikstrand J, Wedel H, Ghali J, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F.

Card Electrophysiol Rev. 2003 Sep;7(3):264-75.

PMID:
14739726
8.
9.

Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes.

Patel K, Fonarow GC, Ekundayo OJ, Aban IB, Kilgore ML, Love TE, Kitzman DW, Gheorghiade M, Allman RM, Ahmed A.

Int J Cardiol. 2014 May 15;173(3):393-401. doi: 10.1016/j.ijcard.2014.03.005.

10.
11.

Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction.

Farasat SM, Bolger DT, Shetty V, Menachery EP, Gerstenblith G, Kasper EK, Najjar SS.

Am J Cardiol. 2010 Jan 15;105(2):229-34. doi: 10.1016/j.amjcard.2009.09.008.

PMID:
20102924
12.

Pharmacotherapy of heart failure with normal ejection fraction (HFNEF)--a systematic review.

Rajagopalan S, Arora A, Shafiq N, Reddy S S, Pandhi P, Mittal N, Malhotra S.

Br J Clin Pharmacol. 2011 Sep;72(3):369-80. doi: 10.1111/j.1365-2125.2011.03998.x. Review.

13.

Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction.

El-Refai M, Peterson EL, Wells K, Swadia T, Sabbah HN, Spertus JA, Williams LK, Lanfear DE.

J Card Fail. 2013 Feb;19(2):73-9. doi: 10.1016/j.cardfail.2012.11.011.

14.

In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.

Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, Metra M, Lucci D, Gonzini L, Cirrincione V, Montagna L, Di Lenarda A, Maggioni AP, Tavazzi L; IN HF Outcome Investigators..

Int J Cardiol. 2014 May 1;173(2):163-9. doi: 10.1016/j.ijcard.2014.02.018.

PMID:
24630337
15.

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.

Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E.

BMJ. 2013 Jan 16;346:f55. doi: 10.1136/bmj.f55. Review. Erratum in: BMJ. 2013;346:f596.

16.

Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.

Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJ, Van Veldhuisen DJ.

JACC Heart Fail. 2013 Feb;1(1):21-8. doi: 10.1016/j.jchf.2012.09.002. Review.

PMID:
24621795
17.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators..

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
18.

Influence of global region on outcomes in heart failure β-blocker trials.

O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis-Stough W, Davis GW, Bristow MR.

J Am Coll Cardiol. 2011 Aug 23;58(9):915-22. doi: 10.1016/j.jacc.2011.03.057.

19.

Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.

Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J; MERIT-HF Study Group..

Am Heart J. 2001 Sep;142(3):502-11.

PMID:
11526365
20.

N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).

Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators..

Eur J Heart Fail. 2013 Oct;15(10):1148-56. doi: 10.1093/eurjhf/hft076.

Supplemental Content

Support Center